RESUMEN
Multiple sclerosis (MS) is a highly disabling, progressive neurodegenerative disease with no curative treatment available. Although significant progress has been made in understanding how MS develops, there remain aspects of disease pathogenesis that are yet to be fully elucidated. In this regard, studies have shown that dysfunctional adenosinergic signaling plays a pivotal role, as patients with MS have altered levels adenosine (ADO), adenosine receptors and proteins involved in the generation and termination of ADO signaling, such as CD39 and adenosine deaminase (ADA). We have therefore performed a literature review regarding the involvement of the adenosinergic system in the development of MS and propose mechanisms by which the modulation of this system can support drug development and repurposing.
Asunto(s)
Esclerosis Múltiple , Enfermedades Neurodegenerativas , Receptores Purinérgicos P1 , Adenosina/inmunología , Adenosina Desaminasa/inmunología , Apirasa/inmunología , Humanos , Esclerosis Múltiple/etiología , Esclerosis Múltiple/inmunología , Esclerosis Múltiple/terapia , Enfermedades Neurodegenerativas/etiología , Enfermedades Neurodegenerativas/inmunología , Enfermedades Neurodegenerativas/terapia , Receptores Purinérgicos P1/inmunología , Transducción de SeñalRESUMEN
Upon SARS-CoV-2 infection, viral intermediates specifically activate the IFN response through MDA5-mediated sensing and accordingly induce ADAR1 p150 expression, which might lead to viral A-to-I RNA editing. Here, we developed an RNA virus-specific editing identification pipeline, surveyed 7622 RNA-seq data from diverse types of samples infected with SARS-CoV-2, and constructed an atlas of A-to-I RNA editing sites in SARS-CoV-2. We found that A-to-I editing was dynamically regulated, varied between tissue and cell types, and was correlated with the intensity of innate immune response. On average, 91 editing events were deposited at viral dsRNA intermediates per sample. Moreover, editing hotspots were observed, including recoding sites in the spike gene that affect viral infectivity and antigenicity. Finally, we provided evidence that RNA editing accelerated SARS-CoV-2 evolution in humans during the epidemic. Our study highlights the ability of SARS-CoV-2 to hijack components of the host antiviral machinery to edit its genome and fuel its evolution, and also provides a framework and resource for studying viral RNA editing.
Asunto(s)
COVID-19/inmunología , Inmunidad Innata/inmunología , Edición de ARN/inmunología , SARS-CoV-2/inmunología , Adenosina Desaminasa/genética , Adenosina Desaminasa/inmunología , Adenosina Desaminasa/metabolismo , Enzima Convertidora de Angiotensina 2/genética , Enzima Convertidora de Angiotensina 2/inmunología , Enzima Convertidora de Angiotensina 2/metabolismo , Secuencia de Bases , Sitios de Unión/genética , COVID-19/genética , COVID-19/virología , Evolución Molecular , Expresión Génica/inmunología , Humanos , Inmunidad Innata/genética , Helicasa Inducida por Interferón IFIH1/genética , Helicasa Inducida por Interferón IFIH1/inmunología , Helicasa Inducida por Interferón IFIH1/metabolismo , Mutación , Unión Proteica , Edición de ARN/genética , Proteínas de Unión al ARN/genética , Proteínas de Unión al ARN/inmunología , Proteínas de Unión al ARN/metabolismo , SARS-CoV-2/genética , SARS-CoV-2/fisiología , Homología de Secuencia de Ácido Nucleico , Glicoproteína de la Espiga del Coronavirus/genética , Glicoproteína de la Espiga del Coronavirus/inmunología , Glicoproteína de la Espiga del Coronavirus/metabolismoRESUMEN
ADARs (adenosine deaminases acting on RNA) are known for their adenosine-to-inosine RNA editing activity, and most recently, for their role in preventing aberrant dsRNA-response by activation of dsRNA sensors (i.e., RIG-I-like receptor homologs). However, it is still unclear whether suppressing spurious dsRNA-response represents the ancestral role of ADARs in bilaterians. As a first step to address this question, we identified ADAR1 and ADAR2 homologs in the planarian Schmidtea mediterranea, which is evolutionarily distant from canonical lab models (e.g., flies and nematodes). Our results indicate that knockdown of either planarian adar1 or adar2 by RNA interference (RNAi) resulted in upregulation of dsRNA-response genes, including three planarian rig-I-like receptor (prlr) homologs. Furthermore, independent knockdown of adar1 and adar2 reduced the number of infected cells with a dsRNA virus, suggesting they suppress a bona fide anti-viral dsRNA-response activity. Knockdown of adar1 also resulted in lesion formation and animal lethality, thus attesting to its essentiality. Simultaneous knockdown of adar1 and prlr1 rescued adar1(RNAi)-dependent animal lethality and rescued the dsRNA-response, suggesting that it contributes to the deleterious effect of adar1 knockdown. Finally, we found that ADAR2, but not ADAR1, mediates mRNA editing in planarians, suggesting at least in part non-redundant activities for planarians ADARs. Our results underline the essential role of ADARs in suppressing activation of harmful dsRNA-response in planarians, thus supporting it as their ancestral role in bilaterians. Our work also set the stage to study further and better understand the regulatory mechanisms governing anti-viral dsRNA-responses from an evolutionary standpoint using planarians as a model.
Asunto(s)
Adenosina Desaminasa/inmunología , Adenosina Desaminasa/metabolismo , Planarias/fisiología , ARN Bicatenario/inmunología , Animales , Virosis/inmunologíaRESUMEN
The best and most effective way to combat pandemics is to use effective vaccines and live attenuated vaccines are among the most effective vaccines. However, one of the major problems is the length of time it takes to get the attenuated vaccines. Today, the CRISPR toolkit (Clustered Regularly Inerspaced Short Palindromic Repeats) has made it possible to make changes with high efficiency and speed. Using this toolkit to make point mutations on the RNA virus's genome in a coculture of permissive and nonpermissive cells and under controlled conditions can accelerate changes in the genome and accelerate natural selection to obtain live attenuated vaccines.
Asunto(s)
Vacunas contra la COVID-19/genética , COVID-19/prevención & control , Sistemas CRISPR-Cas , Edición Génica/métodos , Tasa de Mutación , SARS-CoV-2/genética , Proteínas Virales/genética , Desaminasas APOBEC/genética , Desaminasas APOBEC/inmunología , Adenosina Desaminasa/genética , Adenosina Desaminasa/inmunología , Proteínas Bacterianas/genética , Proteínas Bacterianas/inmunología , COVID-19/inmunología , Vacunas contra la COVID-19/biosíntesis , Endonucleasas/genética , Endonucleasas/inmunología , Expresión Génica , Genoma Viral , Humanos , Proteínas de Unión al ARN/genética , Proteínas de Unión al ARN/inmunología , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , SARS-CoV-2/inmunología , Selección Genética , Vacunas Atenuadas , Proteínas Virales/inmunologíaRESUMEN
OBJECTIVE: We compared diagnostic accuracy of pleural fluid adenosine deaminase (ADA) and interferon-gamma (IFN-γ) in diagnosing tuberculous pleural effusion (TPE) through systematic review and comparative meta-analysis. METHODS: We queried PubMed and Embase databases to identify studies providing paired data for sensitivity and specificity of both pleural fluid ADA and IFN-γ for diagnosing TPE. We used hierarchical summary receiver operating characteristic (HSROC) plots and HSROC meta-regression to model individual and comparative diagnostic performance of the two tests. RESULTS: We retrieved 376 citations and included 45 datasets from 44 publications (4974 patients) in our review. Summary estimates for sensitivity and specificity for ADA were 0.88 (95% CI 0.85-0.91) and 0.91 (95% CI 0.89-0.92), while for IFN-γ they were 0.91 (95% CI 0.89-0.94) and 0.96 (95% CI 0.94-0.97), respectively. HSROC plots showed consistently greater diagnostic accuracy for IFN-γ over ADA across the entire range of observations. HSROC meta-regression using test-type as covariate yielded a relative diagnostic odds ratio of 2.22 (95% CI 1.68-2.94) in favour of IFN-γ, along with better summary sensitivity and specificity figures. No prespecified subgroup variable significantly influenced the summary diagnostic accuracy estimates. CONCLUSION: Pleural fluid IFN-γ estimation has better diagnostic accuracy than ADA estimation for diagnosis of TPE.
Asunto(s)
Tuberculosis Pleural , Adenosina Desaminasa/inmunología , Biomarcadores , Humanos , Interferón gamma/inmunología , Sensibilidad y Especificidad , Tuberculosis Pleural/diagnóstico , Tuberculosis Pleural/inmunologíaRESUMEN
Four cases of idiopathic multi-centric Castleman disease (iMCD) reportedly have variants in hereditary autoinflammatory disease-related genes; however, the frequency and role of these variants in iMCD is still unknown. We therefore investigated such gene variants among patients with iMCD and aimed to reveal the relationship between iMCD and autoinflammatory disease-related genes. We reviewed 14 Japanese iMCD patients who were recruited between January 2015 and September 2019. All patients met both the Japanese tentative diagnostic criteria for Castleman disease and the international consensus diagnostic criteria for iMCD. We performed genetic analyses for 31 autoinflammatory disease-related genes by targeted next-generation sequencing. The MEFV gene variants were observed in 10 of 14 patients with iMCD. Although iMCD had a high percentage of exons 2 or 3 variants of MEFV, comparison of data from healthy Japanese subjects indicated that there was no significant difference in the percentage between healthy Japanese subjects and patients with iMCD. Variants of uncertain significance (VUS) in the TNFRSF1A and CECR1 genes were observed in two of the patients, respectively. We divided patients into two groups-those with MEFV variants (excluding E148Q variants) and those without MEFV variants-and compared the clinical characteristics between these two groups. Patients with MEFV variants, excluding E148Q variants, exhibited a significantly higher likelihood of fever and significantly lower levels of hemoglobin than those lacking MEFV variants. Our results indicated that patients with iMCD tended to have a high frequency of MEFV gene variants and the presence of such variants can affect iMCD clinical phenotypes.
Asunto(s)
Adenosina Desaminasa , Enfermedad de Castleman , Enfermedades Autoinflamatorias Hereditarias , Péptidos y Proteínas de Señalización Intercelular , Mutación Missense , Pirina , Receptores Tipo I de Factores de Necrosis Tumoral , Adenosina Desaminasa/genética , Adenosina Desaminasa/inmunología , Adulto , Anciano , Sustitución de Aminoácidos , Enfermedad de Castleman/genética , Enfermedad de Castleman/inmunología , Exones , Femenino , Enfermedades Autoinflamatorias Hereditarias/genética , Enfermedades Autoinflamatorias Hereditarias/inmunología , Humanos , Péptidos y Proteínas de Señalización Intercelular/genética , Péptidos y Proteínas de Señalización Intercelular/inmunología , Masculino , Persona de Mediana Edad , Pirina/genética , Pirina/inmunología , Receptores Tipo I de Factores de Necrosis Tumoral/genética , Receptores Tipo I de Factores de Necrosis Tumoral/inmunologíaRESUMEN
OBJECTIVES: The Cat Eye Syndrome Critical Region, Candidate 1 (CECR1) gene encoding adenosine deaminase 2 (ADA2) is mainly expressed by macrophages. Given the immunomodulatory functions of butyrate, we examined the effect of butyrate on CECR1 expression of macrophages and the relationship between ADA2 and M1/M2 macrophages-associated chemokines in pleural fluid of patients with tuberculous pleural effusion (TPE). METHODS: Expression of CECR1 was evaluated in lipopolysaccharide (LPS)-stimulated and/or butyrate treated THP-1 cells. The role of CECR1 on butyrate-induced immune response was evaluated using siRNA transfected THP-1 cells. M1/M2 chemokines and ADA2 were measured in pleural fluid of patients with TPE. RESULTS: Butyrate promoted the expression of CECR1 and M2-macrophage markers in THP-1 cells. CECR1 was found to be involved in regulating M2 polarization in THP-1 cells treated with LPS and butyrate. Among chemokines measured in pleural fluid of patients with TPE, there was a significant negative correlation between CCL21 and ADA2 levels and between CCL25 and ADA2 levels, and a significant positive correlation between TGF-ß and ADA2 levels and between IL-22 and ADA2 levels. CONCLUSIONS: CECR1 played an important role in the butyrate-modulated inflammatory responses in LPS-stimulated THP-1 cells. ADA2 may exert anti-inflammatory effects during the process of pleural inflammation in patients with TPE.
Asunto(s)
Adenosina Desaminasa/genética , Adenosina Desaminasa/inmunología , Butiratos/farmacología , Quimiocinas/inmunología , Péptidos y Proteínas de Señalización Intercelular/genética , Péptidos y Proteínas de Señalización Intercelular/inmunología , Macrófagos/inmunología , Derrame Pleural/inmunología , Tuberculosis Pleural/inmunología , Adenosina Desaminasa/metabolismo , Quimiocinas/metabolismo , Citocinas/metabolismo , Humanos , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Lipopolisacáridos/farmacología , Activación de Macrófagos/efectos de los fármacos , Derrame Pleural/metabolismo , Células THP-1RESUMEN
BACKGROUND: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive inflammatory disease caused by loss-of-function mutations in both alleles of the ADA2 gene. Most patients with DADA2 exhibit systemic vasculopathy consistent with polyarteritis nodosa, but large phenotypic variability has been reported, and the pathogenesis of DADA2 remains unclear. OBJECTIVES: This study sought to assess the clinical and genetic characteristics of Japanese patients with DADA2 and to gain insight into the pathogenesis of DADA2 by multi-omics analysis. METHODS: Clinical and genetic data were collected from 8 Japanese patients with DADA2 diagnosed between 2016 and 2019. ADA2 variants in this cohort were functionally analyzed by in vitro overexpression analysis. PBMCs from 4 patients with DADA2 were subjected to transcriptome and proteome analyses. Patient samples were collected before and after introduction of anti- TNF-α therapies. Transcriptome data were compared with those of normal controls and patients with other autoinflammatory diseases. RESULTS: Five novel ADA2 variants were identified in these 8 patients and were confirmed pathogenic by in vitro analysis. Anti-TNF-α therapy controlled inflammation in all 8 patients. Transcriptome and proteome analyses showed that upregulation of type II interferon signaling was characteristic of DADA2. Network analysis identified STAT1 as a key regulator and a hub molecule in DADA2 pathogenesis, a finding supported by the hyperactivation of STAT1 in patients' monocytes and B cells after IFN-γ stimulation. CONCLUSIONS: Type II interferon signaling and STAT1 are associated with the pathogenesis of DADA2.
Asunto(s)
Adenosina Desaminasa/deficiencia , Agammaglobulinemia/inmunología , Péptidos y Proteínas de Señalización Intercelular/deficiencia , Interferón gamma/inmunología , Leucocitos Mononucleares/inmunología , Factor de Transcripción STAT1/inmunología , Inmunodeficiencia Combinada Grave/inmunología , Adenosina Desaminasa/inmunología , Adolescente , Adulto , Agammaglobulinemia/genética , Agammaglobulinemia/patología , Pueblo Asiatico , Niño , Preescolar , Femenino , Perfilación de la Expresión Génica , Humanos , Lactante , Péptidos y Proteínas de Señalización Intercelular/inmunología , Interferón gamma/genética , Japón , Leucocitos Mononucleares/patología , Masculino , Proteómica , Factor de Transcripción STAT1/genética , Inmunodeficiencia Combinada Grave/genética , Inmunodeficiencia Combinada Grave/patologíaRESUMEN
ADAR1-mediated deamination of adenosines in long double-stranded RNAs plays an important role in modulating the innate immune response. However, recent investigations based on metatranscriptomic samples of COVID-19 patients and SARS-COV-2-infected Vero cells have recovered contrasting findings. Using RNAseq data from time course experiments of infected human cell lines and transcriptome data from Vero cells and clinical samples, we prove that A-to-G changes observed in SARS-COV-2 genomes represent genuine RNA editing events, likely mediated by ADAR1. While the A-to-I editing rate is generally low, changes are distributed along the entire viral genome, are overrepresented in exonic regions, and are (in the majority of cases) nonsynonymous. The impact of RNA editing on virus-host interactions could be relevant to identify potential targets for therapeutic interventions.
Asunto(s)
Adenosina Desaminasa/genética , COVID-19/genética , Genoma Viral , Interacciones Huésped-Patógeno/genética , Edición de ARN , ARN Viral/genética , Proteínas de Unión al ARN/genética , SARS-CoV-2/genética , Adenosina/metabolismo , Adenosina Desaminasa/inmunología , Animales , COVID-19/metabolismo , COVID-19/virología , Línea Celular Tumoral , Chlorocebus aethiops , Proteína 58 DEAD Box/genética , Proteína 58 DEAD Box/inmunología , Desaminación , Células Epiteliales/inmunología , Células Epiteliales/virología , Interacciones Huésped-Patógeno/inmunología , Humanos , Inmunidad Innata , Inosina/metabolismo , Helicasa Inducida por Interferón IFIH1/genética , Helicasa Inducida por Interferón IFIH1/inmunología , Interferón beta/genética , Interferón beta/inmunología , ARN Bicatenario/genética , ARN Bicatenario/inmunología , ARN Viral/inmunología , Proteínas de Unión al ARN/inmunología , Receptores Inmunológicos/genética , Receptores Inmunológicos/inmunología , SARS-CoV-2/metabolismo , SARS-CoV-2/patogenicidad , Transcriptoma , Células VeroRESUMEN
Adenosine deaminase 2 deficiency (DADA2) is an autoinflammatory disease characterized by inflammatory vasculopathy, early strokes associated often with hypogammaglobulinemia. Pure red cell aplasia, thrombocytopenia, and neutropenia have been reported. The defect is due to biallelic loss of function of ADA2 gene, coding for a protein known to regulate the catabolism of extracellular adenosine. We therefore investigated immune phenotype and B- and T-cell responses in 14 DADA2 patients to address if ADA2 mutation affects B- and T-cell function. Here, we show a significant decrease in memory B cells, in particular class switch memory, and an expansion of CD21low B cells in DADA2 patients. In vitro stimulated B lymphocytes were able to secrete nonfunctional ADA2 protein, suggesting a cell intrinsic defect resulting in an impairment of B-cell proliferation and differentiation. Moreover, CD4+ and CD8+ T cells were diminished; however, the frequency of circulating T follicular helper cells was significantly increased but they had an impairment in IL-21 production possibly contributing to an impaired B cell help. Our findings suggest that ADA2 mutation could lead to a B-cell intrinsic defect but also to a defective Tfh cell function, which could contribute to the immunodeficient phenotype reported in DADA2 patients.
Asunto(s)
Adenosina Desaminasa/deficiencia , Agammaglobulinemia/inmunología , Linfocitos B/inmunología , Péptidos y Proteínas de Señalización Intercelular/deficiencia , Inmunodeficiencia Combinada Grave/inmunología , Células T Auxiliares Foliculares/inmunología , Adenosina Desaminasa/genética , Adenosina Desaminasa/inmunología , Adolescente , Adulto , Agammaglobulinemia/enzimología , Agammaglobulinemia/genética , Linfocitos B/enzimología , Linfocitos B/patología , Estudios de Casos y Controles , Diferenciación Celular , Proliferación Celular , Niño , Preescolar , Femenino , Humanos , Memoria Inmunológica , Inmunofenotipificación , Técnicas In Vitro , Lactante , Recién Nacido , Péptidos y Proteínas de Señalización Intercelular/genética , Péptidos y Proteínas de Señalización Intercelular/inmunología , Interleucinas/biosíntesis , Activación de Linfocitos , Masculino , Mutación , Inmunodeficiencia Combinada Grave/enzimología , Inmunodeficiencia Combinada Grave/genética , Células T Auxiliares Foliculares/patologíaAsunto(s)
Adenosina Desaminasa/inmunología , Autoanticuerpos/sangre , Dermatomiositis/diagnóstico , Lupus Eritematoso Sistémico/diagnóstico , Proteínas de Unión al ARN/inmunología , Adenosina Desaminasa/genética , Adulto , Empalme Alternativo , Autoanticuerpos/inmunología , Dermatomiositis/sangre , Dermatomiositis/genética , Dermatomiositis/inmunología , Femenino , Humanos , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/genética , Lupus Eritematoso Sistémico/inmunología , Masculino , Isoformas de Proteínas/genética , Isoformas de Proteínas/inmunología , Proteínas de Unión al ARN/genéticaRESUMEN
The absence of adenosine deaminase (ADA) causes severe combined immune deficiency (SCID), which has been treated with PEGylated bovine-extracted ADA (ADAGEN). ADAGEN was recently replaced by a PEGylated recombinant bovine ADA, expressed in Escherichia coli (elapegademase, ELA-ADA). Limited information on ELA-ADA is available. ADA enzymatic activity of ELA-ADA and ADAGEN was assessed in vitro at diverse dilutions. ADA activity and immune reconstitution in an ADA-SCID patient treated with ELA-ADA were compared with age-matched patients previously treated with ADAGEN. ADA activity and thymus reconstitution were evaluated in ADA-deficient mice following ELA-ADA or ADAGEN administered from 7 days postpartum. In vitro, ADA activity of ELA-ADA and ADAGEN were similar at all dilutions. In an ADA-SCID patient, ELA-ADA treatment led to a marked increase in trough plasma ADA activity, which was 20% higher than in a patient previously treated with ADAGEN. A marked increase in T cell numbers and generation of naive T cells was evident following 3 months of ELA-ADA treatment, while T cell numbers increased following 4 months in 3 patients previously treated with ADAGEN. T cell proliferations stimulation normalized and thymus shadow became evident following ELA-ADA treatment. ADA activity was significantly increased in the blood of ADA-deficient mice following ELA-ADA compared to ADAGEN, while both treatments improved the mice weights, the weight, number of cells in their thymus and thymocyte subpopulations. ELA-ADA has similar in- vitro and possibly better in-vivo activity than ADAGEN. Future studies will determine whether ELA-ADA results in improved long-term immune reconstitution.
Asunto(s)
Adenosina Desaminasa/deficiencia , Agammaglobulinemia , Inmunodeficiencia Combinada Grave , Linfocitos T , Timo , Adenosina Desaminasa/sangre , Adenosina Desaminasa/efectos de los fármacos , Adenosina Desaminasa/inmunología , Adenosina Desaminasa/farmacología , Agammaglobulinemia/sangre , Agammaglobulinemia/inmunología , Animales , Humanos , Ratones , Ratones Noqueados , Inmunodeficiencia Combinada Grave/sangre , Inmunodeficiencia Combinada Grave/inmunología , Linfocitos T/inmunología , Linfocitos T/metabolismo , Linfocitos T/patología , Timo/inmunología , Timo/metabolismo , Timo/patologíaAsunto(s)
Adenosina Desaminasa/deficiencia , Agammaglobulinemia/tratamiento farmacológico , Terapia de Reemplazo Enzimático/métodos , Complicaciones del Embarazo/tratamiento farmacológico , Inmunodeficiencia Combinada Grave/tratamiento farmacológico , Adenosina Desaminasa/administración & dosificación , Adenosina Desaminasa/inmunología , Adulto , Agammaglobulinemia/inmunología , Esquema de Medicación , Femenino , Humanos , Embarazo , Complicaciones del Embarazo/inmunología , Inmunodeficiencia Combinada Grave/inmunología , Resultado del TratamientoAsunto(s)
Adenosina Desaminasa/deficiencia , Agammaglobulinemia/genética , Péptidos y Proteínas de Señalización Intercelular/genética , Sitios de Empalme de ARN/genética , Empalme del ARN/inmunología , Inmunodeficiencia Combinada Grave/genética , Adenosina Desaminasa/genética , Adenosina Desaminasa/inmunología , Agammaglobulinemia/diagnóstico , Agammaglobulinemia/inmunología , Niño , Femenino , Homocigoto , Humanos , Péptidos y Proteínas de Señalización Intercelular/deficiencia , Mutación con Pérdida de Función , Mutación , Empalme del ARN/genética , Inmunodeficiencia Combinada Grave/diagnóstico , Inmunodeficiencia Combinada Grave/inmunologíaRESUMEN
RNA editing by adenosine deaminases of the ADAR family attracts a growing interest of researchers, both zoologists studying ecological and evolutionary plasticity of invertebrates and medical biochemists focusing on the mechanisms of cancer and other human diseases. These enzymes deaminate adenosine residues in the double-stranded (ds) regions of RNA with the formation of inosine. As a result, some RNAs change their three-dimensional structure and functions. Adenosine-to-inosine editing in the mRNA coding sequences may cause amino acid substitutions in the encoded proteins. Here, we reviewed current concepts on the functions of two active ADAR isoforms identified in mammals (including humans). The ADAR1 protein, which acts non-specifically on extended dsRNA regions, is capable of immunosuppression via inactivation of the dsRNA interactions with specific sensors inducing the cell immunity. Expression of a specific ADAR1 splicing variant is regulated by the type I interferons by the negative feedback mechanism. It was shown that immunosuppressing effects of ADAR1 facilitate progression of some types of cancer. On the other hand, changes in the amino acid sequences resulting from the mRNA editing by the ADAR enzymes can result in the formation of neoantigens that can activate the antitumor immunity. The ADAR2 isoform acts on RNA more selectively; its function is associated with the editing of mRNA coding regions and can lead to the amino acid substitutions, in particular, those essential for the proper functioning of some neurotransmitter receptors in the central nervous system.
Asunto(s)
Adenosina Desaminasa/metabolismo , Carcinogénesis/metabolismo , Plasticidad Neuronal/fisiología , Edición de ARN/fisiología , Proteínas de Unión al ARN/metabolismo , Adenosina Desaminasa/inmunología , Secuencia de Aminoácidos , Animales , Senescencia Celular/fisiología , Humanos , Inosina/metabolismo , Interferón Tipo I/metabolismo , Proteoma/metabolismo , ARN Bicatenario/metabolismo , Proteínas de Unión al ARN/inmunologíaRESUMEN
Background: Inherited defects in adenosine deaminase (ADA) cause severe immune deficiency, which can be corrected by ADA enzyme replacement therapy (ERT). Additionally, ADA-deficient patients suffer from hearing impairment. We hypothesized that ADA-deficient (-/-) mice also exhibit hearing abnormalities and that ERT from an early age will improve the hearing and immune defects in these mice. Methods: Auditory brainstem evoked responses, organ weights, thymocytes numbers, and subpopulations, lymphocytes in peripheral blood as well as T lymphocytes in spleen were analyzed in ADA-/- and ADA-proficient littermate post-partum (pp). The cochlea was visualized by scanning electron microscopy (SEM). The effects of polyethylene glycol conjugated ADA (PEG-ADA) ERT or 40% oxygen initiated at 7 days pp on the hearing and immune abnormalities were assessed. Results: Markedly abnormal hearing thresholds responses were found in ADA-/- mice at low and medium tone frequencies. SEM demonstrated extensive damage to the cochlear hair cells of ADA-/- mice, which were splayed, short or missing, correlating with the hearing deficits. The hearing defects were not reversed when hypoxia in ADA-/- mice was corrected. Progressive immune abnormalities were detected in ADA-/- mice from 4 days pp, initially affecting the thymus followed by peripheral lymphocytes and T cells in the spleen. ERT initiated at 7 days pp significantly improved the hearing of ADA-/- mice as well as the number of thymocytes and T lymphocytes, although not all normalized. Conclusions: ADA deficiency is associated with hearing deficits and damage to cochlear hair cells. Early initiation of ERT improves the hearing and immune abnormalities.
Asunto(s)
Adenosina Desaminasa/deficiencia , Adenosina Desaminasa/farmacología , Agammaglobulinemia/complicaciones , Agammaglobulinemia/inmunología , Células Ciliadas Auditivas/patología , Pérdida Auditiva/etiología , Inmunodeficiencia Combinada Grave/complicaciones , Inmunodeficiencia Combinada Grave/inmunología , Adenosina Desaminasa/inmunología , Agammaglobulinemia/patología , Animales , Terapia de Reemplazo Enzimático , Ratones , Ratones Noqueados , Inmunodeficiencia Combinada Grave/patologíaRESUMEN
Viral and cellular double-stranded RNA (dsRNA) is recognized by cytosolic innate immune sensors, including RIG-I-like receptors. Some cytoplasmic dsRNA is commonly present in cells, and one source is mitochondrial dsRNA, which results from bidirectional transcription of mitochondrial DNA (mtDNA). Here we demonstrate that Trp53 mutant mouse embryonic fibroblasts contain immune-stimulating endogenous dsRNA of mitochondrial origin. We show that the immune response induced by this dsRNA is mediated via RIG-I-like receptors and leads to the expression of type I interferon and proinflammatory cytokine genes. The mitochondrial dsRNA is cleaved by RNase L, which cleaves all cellular RNA including mitochondrial mRNAs, increasing activation of RIG-I-like receptors. When mitochondrial transcription is interrupted there is a subsequent decrease in this immune-stimulatory dsRNA. Our results reveal that the role of p53 in innate immunity is even more versatile and complex than previously anticipated. Our study, therefore, sheds new light on the role of endogenous RNA in diseases featuring aberrant immune responses.
Asunto(s)
Adenosina Desaminasa/genética , Proteína 58 DEAD Box/genética , Inmunidad Innata/genética , ARN Bicatenario/genética , ARN Mitocondrial/genética , Proteína p53 Supresora de Tumor/genética , Proteínas Adaptadoras Transductoras de Señales , Adenosina Desaminasa/deficiencia , Adenosina Desaminasa/inmunología , Animales , Proteínas Portadoras/genética , Proteínas Portadoras/inmunología , Proteína 58 DEAD Box/inmunología , Embrión de Mamíferos , Endorribonucleasas/genética , Endorribonucleasas/inmunología , Fibroblastos/citología , Fibroblastos/inmunología , Factor 7 Regulador del Interferón/genética , Factor 7 Regulador del Interferón/inmunología , Helicasa Inducida por Interferón IFIH1/genética , Helicasa Inducida por Interferón IFIH1/inmunología , Péptidos y Proteínas de Señalización Intracelular , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas/genética , Proteínas/inmunología , ARN Bicatenario/inmunología , ARN Mitocondrial/inmunología , Proteínas de Unión al ARN , Transcripción Genética , Transfección , Proteína p53 Supresora de Tumor/deficiencia , Proteína p53 Supresora de Tumor/inmunologíaRESUMEN
Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target.
Asunto(s)
Adenosina Desaminasa/metabolismo , Terapia Genética/métodos , Inmunoterapia/métodos , Neoplasias/terapia , ARN Bicatenario/metabolismo , Proteínas de Unión al ARN/metabolismo , Adenosina Desaminasa/genética , Adenosina Desaminasa/inmunología , Animales , Sistemas CRISPR-Cas , Supervivencia Celular , Edición Génica , Regulación Enzimológica de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunidad Innata , Helicasa Inducida por Interferón IFIH1/genética , Helicasa Inducida por Interferón IFIH1/metabolismo , Neoplasias/enzimología , Neoplasias/genética , Neoplasias/inmunología , Edición de ARN , ARN Bicatenario/genética , ARN Bicatenario/inmunología , Proteínas de Unión al ARN/genética , Proteínas de Unión al ARN/inmunologíaAsunto(s)
Adenosina Desaminasa/deficiencia , Agammaglobulinemia , Neutropenia , Inmunodeficiencia Combinada Grave , Adenosina Desaminasa/sangre , Adenosina Desaminasa/inmunología , Agammaglobulinemia/sangre , Agammaglobulinemia/inmunología , Agammaglobulinemia/patología , Femenino , Humanos , Masculino , Neutropenia/sangre , Neutropenia/inmunología , Neutropenia/patología , Inmunodeficiencia Combinada Grave/sangre , Inmunodeficiencia Combinada Grave/inmunología , Inmunodeficiencia Combinada Grave/patologíaRESUMEN
BACKGROUND: Interferon (IFN)-α is widely used for the treatment of chronic hepatitis B (CHB) infection due to the high rate of hepatitis B surface antigen (HBsAg) seroconversion. However, IFN-α treatment has a number of side effects. Thus, identification of molecular biomarkers to predict IFN-α therapeutic effect would be useful in the clinic. In this study, we aimed to investigate the role of retinoic acid-inducible gene-I (RIG-I) in prediction of IFN-α curative effect of CHB patients. METHODS: A total of 65 CHB patients treated with pegylated IFN-α weekly for 48 weeks were enrolled. Real-time PCR was performed for detection of RIG-I and IFN-stimulated gene (ISG) expression. In vitro, the HepG2 cells were transfected with siRNA and levels of RIG-I and anti-HBV proteins were detected by western blot. The P-values were calculated in SPSS 18.0. The statistical significance level was accepted as P<0.05. RESULTS: In this study, we found RIG-I expression in peripheral blood mononuclear cells was higher in responder than non-responder CHB patients treated with IFN-α therapy. In HBV-transfected HepG2 and Huh7 cells, RIG-I enhanced IFN-α response by promoting anti-HBV protein expression such as double-stranded RNA-dependent protein kinase (PKR), oligoadenylate synthetase (OAS), adenosine deaminase (ADAR1) and Mx protein. Knocking down of RIG-I could downregulate the expression of these proteins. Inhibited RIG-I expression by RIG-I siRNA deceased STAT1 phosphorylation. CONCLUSIONS: Our results revealed RIG-I enhanced IFN-α response by promoting antiviral protein expression via the STAT1 pathway. RIG-I may be a new predictive factor for prediction of IFN-α efficacy in CHB patients.